66 results on '"Kullberg, Bart-Jan"'
Search Results
2. 231. Outcomes by Baseline Pathogen and Susceptibility in the ReSTORE Phase 3 Trial of Rezafungin Once Weekly Compared with Caspofungin Once Daily in Patients with Candidemia and/or Invasive Candidiasis
3. Identifying platelet-derived factors as amplifiers ofB. burgdorferi-induced cytokine production
4. The Initial QuantiFERON-Lyme Prototype is Unsuitable for European Patients
5. EORTC/MSGERC Definitions of Invasive Fungal Diseases: Summary of Activities of the Intensive Care Unit Working Group
6. 147. Clinical Safety and Efficacy of Novel Antifungal, Fosmanogepix, in the Treatment of Candidemia: Results from a Phase 2 Proof of Concept Trial
7. 1157. Clinical Safety, Efficacy, and Pharmacokinetics of Fosmanogepix, a Novel First-in-class Antifungal, in Patients with Renal Insufficiency: Subset Analysis from a Phase 2 Candidemia Trial
8. An Exaggerated Monocyte-Derived Cytokine Response to Candida Hyphae in Patients With Recurrent Vulvovaginal Candidiasis
9. Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium
10. Appropriate empirical antibiotic use in the emergency department: full compliance matters!
11. Pneumocystis jirovecii pneumonia: still a concern in patients with haematological malignancies and stem cell transplant recipients
12. Quality Indicators for Appropriate Outpatient Parenteral Antimicrobial Therapy in Adults: A Systematic Review and RAND-modified Delphi Procedure
13. A Genome-Wide Functional Genomics Approach Identifies Susceptibility Pathways to Fungal Bloodstream Infection in Humans
14. Isavuconazole Versus Caspofungin in the Treatment of Candidemia and Other Invasive Candida Infections: The ACTIVE Trial
15. Efficacy of anidulafungin in 539 patients with invasive candidiasis: a patient-level pooled analysis of six clinical trials
16. Human genetic susceptibility toCandidainfections
17. Toll-like Receptor 1 Polymorphisms Increase Susceptibility to Candidemia
18. Cytokine Gene Polymorphisms and the Outcome of Invasive Candidiasis: A Prospective Cohort Study
19. Genetic Variation in the Dectin-1/CARD9 Recognition Pathway and Susceptibility to Candidemia
20. The dectin-1/inflammasome pathway is responsible for the induction of protective T-helper 17 responses that discriminate between yeasts and hyphae of Candida albicans
21. ICU-acquired immunosuppression and the risk for secondary fungal infections
22. The Y238X Stop Codon Polymorphism in the Human β-Glucan Receptor Dectin-1 and Susceptibility to Invasive Aspergillosis
23. Early treatment of candidemia in adults: a review
24. 1,25-dihydroxyvitamin D3 Modulates Cytokine Production Induced by Candida albicans: Impact of Seasonal Variation of Immune Responses
25. Variable recognition ofCandida albicansstrains by TLR4 and lectin recognition receptors
26. Novel strategies for the prevention and treatment ofCandidainfections: the potential of immunotherapy
27. Early Proinflammatory Cytokines and C‐Reactive Protein Trends as Predictors of Outcome in Invasive Aspergillosis
28. Recognition ofBorrelia burgdorferiby NOD2 Is Central for the Induction of an Inflammatory Reaction
29. Mycobacterium tuberculosis induces IL-17A responses through TLR4 and dectin-1 and is critically dependent on endogenous IL-1
30. Early Stop Polymorphism in Human DECTIN‐1 Is Associated with IncreasedCandidaColonization in Hematopoietic Stem Cell Transplant Recipients
31. Reply to Kontoyiannis
32. Bypassing Pathogen‐Induced Inflammasome Activation for the Regulation of Interleukin‐1β Production by the Fungal PathogenCandida albicans
33. Guías de práctica clínica para el manejo de la candidiasis: actualización del 2009, de la Infectious Diseases Society of America
34. Clinical Practice Guidelines for the Management Candidiasis: 2009 Update by the Infectious Diseases Society of America
35. Fungal strategies for overcoming host innate immune response
36. Defining Responses to Therapy and Study Outcomes in Clinical Trials of Invasive Fungal Diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria
37. Revised Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group
38. Role of TLR1 and TLR6 in the host defense against disseminated candidiasis
39. Immune Recognition ofCandida albicansβ‐glucan by Dectin‐1
40. Mycobacterium paratuberculosisis recognized by Toll-like receptors and NOD2
41. Endogenous Interleukin (IL)–1α and IL‐1β Are Crucial for Host Defense against Disseminated Candidiasis
42. Impaired dendritic cell function in Crohn’s disease patients with NOD2 3020insC mutation
43. Quality improvement of surgical prophylaxis in Dutch hospitals: evaluation of a multi-site intervention by time series analysis
44. Understanding variation in quality of antibiotic use for community-acquired pneumonia: effect of patient, professional and hospital factors
45. Influence of endogenous pro-inflammatory cytokines on neutrophil-mediated damage ofCandida albicanspseudohyphae, quantified in a modified tetrazolium dye assay
46. Cytokine responses and regulation of interferon-gamma release by human mononuclear cells toAspergillus fumigatusand other filamentous fungi
47. Design of Efficacy Trials of Cytokines in Combination with Antifungal Drugs
48. Recombinant Interleukin‐18 Protects against DisseminatedCandida albicansInfection in Mice
49. Toll-like receptors and the host defense against microbial pathogens: bringing specificity to the innate-immune system
50. Apolipoprotein-E-deficient mice exhibit an increased susceptibility to disseminated candidiasis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.